EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks

Hideyuki Tamai iD, Ryo Shimizu, Naoki Shingaki, Yoshiyuki Mori, Shuya Maeshima, Junya Nuta, Yoshimasa Maeda, Kosaku Moribata, Yosuke Muraki, Hisanobu Deguchi, Izumi Inoue, Takao Maekita und 3 weitere

Hepatitis Research and Treatment · 28.09.2014 · 2014 · 1-8

DOI: 10.1155/2014/748935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatitis Research and Treatment, erschienen am 28.09.2014. Verfasst von Hideyuki Tamai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama Prefecture 641-0012, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of the present study was to predict sustained virological response (SVR) to telaprevir with pegylated interferon (PEG-IFN) and ribavirin using viral response within 2 weeks after therapy initiation. Thirty-six patients with genotype 1 hepatitis C virus (HCV) and high viral load were treated by telaprevir-based triple therapy. SVR was achieved in 72% (26/36) of patients. Significant differences between the SVR group and non-SVR group were noted regarding response to prior PEG-IFN plus ribavirin, interleukin (IL)28B polymorphism, amino acid substitution at core 70, cirrhosis, hyaluronic acid level, and HCV-RNA reduction within 2 weeks. Setting 4.56 logIU/mL as the cut-off value for HCV-RNA reduction at 2 weeks, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 77%, 86%, 95%, 50%, and 79%, respectively, and for neither the IL28B minor allele nor core 70 mutant were 80%, 71%, 91%, 50%, and 78%, respectively. In conclusion, evaluation of viral reduction at 2 weeks or the combination of IL28B polymorphism and amino acid substitution at core 70 are useful for predicting SVR to telaprevir with PEG-IFN and ribavirin therapy.

Autor:innen und Institutionen

  • Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama Prefecture 641-0012, Japan.

ORCID-Profile: Hideyuki Tamai, Jun Kato

Zitieren

APA

Tamai, H., Shimizu, R., Shingaki, N., Mori, Y., Maeshima, S., Nuta, J., Maeda, Y., Moribata, K., Muraki, Y., Deguchi, H., Inoue, I., Maekita, T., Iguchi, M., Kato, J., & Ichinose, M. (2014). Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. Hepatitis Research and Treatment, 2014, 1-8. https://doi.org/10.1155/2014/748935

Vancouver

Tamai H, Shimizu R, Shingaki N, Mori Y, Maeshima S, Nuta J, et al. Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. Hepatitis Research and Treatment. 2014;2014:1-8. doi:10.1155/2014/748935

BibTeX
@article{Tamai2014,
  author = {Tamai, Hideyuki and Shimizu, Ryo and Shingaki, Naoki and Mori, Yoshiyuki and Maeshima, Shuya and Nuta, Junya and Maeda, Yoshimasa and Moribata, Kosaku and Muraki, Yosuke and Deguchi, Hisanobu and Inoue, Izumi and Maekita, Takao and Iguchi, Mikitaka and Kato, Jun and Ichinose, Masao},
  title = {Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks},
  journal = {Hepatitis Research and Treatment},
  year = {2014},
  volume = {2014},
  pages = {1--8},
  doi = {10.1155/2014/748935}
}
Kostenlos starten →